444 results about "Tumor target" patented technology

The invention discloses a bovine serum albumin combined nano antibody and a preparation method and application thereof, the amino acid sequence of the bovine serum albumin combined nano antibody Nb1 is shown as SEQ.ID No.1, the nano antibody Nb not only has high affinity to bovine serum albumin, but also has good binding activity to both human serum albumin and mouse serum albumin, and the nano antibody Nb has high affinity to human serum albumin and mouse serum albumin. And the antibody has a relatively good broad-spectrum application range, and can be widely applied to the aspects of drug half-life period enhancement, tumor targeted therapy and imaging, immunodetection or diagnosis, recombinant albumin purification or enrichment and the like.

The invention relates to the technical field of tumor treatment, in particular to an intelligent decision-making system for tumor precise targeted medication based on individual mutation information, which comprises a data processing layer, a variation annotation and function prediction layer, a knowledge base integration layer and a scheme decision-making engine and report visualization module. According to the intelligent decision-making system for tumor precise targeted medication based on individual mutation information, a rule engine and a prediction model are combined, dynamic priority ranking is output, multi-model fusion decision making is achieved, and clinical scene deep adaptation is achieved by predicting primary and secondary drug resistance, calculating liver and kidney function adjusting dosage and generating a combined medication time sequence scheme; through an individualized drug delivery scheme, combination drug use optimization is achieved, a visual clinical report is generated, clinical executable operation is further strengthened, and through algorithm quantification, a dynamic knowledge graph, AI auxiliary decision making and a clinical operation closed loop, the next-generation technical research direction of a tumor precise drug use system can be represented.

The invention discloses a multi-angle particle therapy system without a rotating rack and a using method thereof, and relates to the technical field of particle therapy equipment, and the treatment system comprises an accelerator, an irradiation system, a control system, a patient supporting system and an imaging system. The patient supporting system comprises a containing and fixing device, a two-dimensional translation system, a rotating system and a multi-degree-of-freedom mechanical positioning system, the containing and fixing device is connected with the two-dimensional translation system, the two-dimensional translation system is connected with the rotating system, and the two-dimensional translation system controls the relative position of a patient and a rotating center; the rotating system rotates a patient to an appointed angle of a treatment plan or cooperates with the imaging system to obtain a three-dimensional image of the patient, and the irradiation system irradiates a tumor target area; the use method comprises the following steps: generating a treatment plan by reconstructing a three-dimensional CT image, and completing irradiation at different angles according to the treatment plan. According to the treatment system, multi-angle irradiation on a patient can be realized under the condition that a rotating rack is not used, and the manufacturing period and cost of the particle treatment system can be reduced.

The invention discloses a tumor radiotherapy dose calibration method, and relates to the technical field of tumor radiotherapy, and the method comprises the steps: collecting multi-modal data in real time through 4D-CT, MRI and the like, extracting dynamic features through space-time registration, calculating a risk organ dose ratio and a tumor target dose deviation rate, and constructing a comprehensive evaluation function. The method has the advantages that the multi-modal dynamic data of the tumor target area are synchronously collected in real time, the space-time joint registration algorithm and the time sequence weight factor are combined, the limitation that existing static calibration depends on fixed parameters is broken through, and the method is suitable for the multi-modal dynamic data of the tumor target area. According to the method, 95% dose coverage of a tumor target region is guaranteed, and meanwhile, organ-endangering peak value receiving amount is controlled within a certain range of a clinical tolerance threshold value, so that the risk of excessive irradiation of normal tissues is reduced, and the radiotherapy dose calibration precision is prompted based on the deviation rate of a traditional method.

The invention discloses a tumor and target region synchronous segmentation method and system based on visual language guidance. The method comprises the following steps: constructing a multi-modal data set fusing a medical image and a clinical text; a unified encoder is adopted to extract shared visual features, a double-branch decoder is adopted to predict a tumor region (GTV) and a clinical target region (CTV) respectively, and information sharing and task differentiation modeling are achieved; introducing a medical pre-training large language model, and respectively extracting language features related to GTV and CTV; a visual language collaborative attention module is designed, dynamic fusion and alignment of visual languages are carried out, task related semantics are guided and enhanced, and redundant information is inhibited; and outputting a precise synchronous segmentation result of the GTV and the CTV after fusing the multi-modal features. Compared with an existing scheme, the problems that the boundary of a tumor target region in a medical image is fuzzy and multi-modal information is insufficient in utilization are effectively solved, the segmentation precision and robustness are remarkably improved, and reliable support is provided for clinical radiotherapy planning.

The invention discloses an enzyme response type KRAS targeted protein degradation chimera as well as a preparation method and application thereof, and belongs to the technical field of tumor targeted therapy. The enzyme response type KRAS targeted protein degradation chimera disclosed by the invention is obtained by covalently linking three parts, namely a KRAS targeted protein degradation chimera, an enzyme response type amino acid sequence and a cell penetrating peptide amino acid sequence, wherein the KRAS targeted protein degradation chimera is obtained by linking a KRAS targeted peptide and a VHL E3 ligase ligand through succinic acid. The enzyme response type KRAS targeted protein degradation chimera releases the KRAS targeted protein degradation chimera under the action of ATG4 enzyme shearing, and shows a relatively strong lung cancer resisting effect in vitro and in vivo. The invention has significant advantages in the aspect of antitumor drugs, and opens up a new field for the development of targeted protein degradation chimera drugs. Enzyme response type KRAS targeted protein degradation chimera molecular structural formula as follows: # imgabs0 #

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention belongs to the field of biomedicine, and particularly relates to polypeptide for targeted blocking of combination of TRIM25 and BRD7 protein and application of the polypeptide. According to the present invention, based on the minimum binding region PRYSPRY structural domain (439 aa-630 aa) of the TRIM25 and the BRD7 protein, the blocking peptide TB16 capable of specifically blocking the mutual binding of the TRIM25 and the BRD7 protein is screened, such that the ubiquitination degradation of the BRD7 is inhibited, and the stability of the BRD7 tumor inhibition protein is improved. The polypeptide drug TB16 can effectively inhibit breast cancer, nasopharynx cancer, ovarian cancer, lung cancer and liver cancer cell proliferation and breast cancer in-vivo tumor growth, has good anti-solid tumor activity, and is expected to become a new anti-tumor targeting drug.

The invention provides a preparation method and application of a CD70 specific nano antibody molecular imaging probe. The probe comprises a tumor targeting group, radionuclide and a bifunctional chelating agent, the tumor targeting group is a CD70 specific nano antibody; the CD70 specific nano antibody is R8B4, and the amino acid sequence of the R8B4 is as shown in SEQ ID No. 1. The probe provided by the invention can realize noninvasive diagnosis of solid tumors such as renal clear cell carcinoma and malignant tumors of a blood system; reabsorption of the compound in the kidney is effectively inhibited through charge adjustment, kidney uptake is remarkably reduced, non-specific signals are reduced, the signal-to-noise ratio during targeted imaging or treatment is increased, and the imaging quality and treatment safety are improved. The probe not only has a wide application prospect in tumor diagnosis, but also provides a new technical support for targeted therapy and individualized precision medical treatment, and has important scientific research and clinical application values.

The invention discloses a 2.5 D dual-scale wavelet SAM-GAN liver tumor target region segmentation method, which comprises the following steps: establishing a segmentation model which is composed of a preprocessing module, a generation module and a discrimination module; an original image enters the preprocessing module and is subjected to neighborhood slice feature aggregation and anatomical perception to generate a 2.5 D image, the 2.5 D image is optimized and enhanced in the generation module and then input into the judgment module, and the judgment module evaluates the authenticity of the image output by the generation module and provides feedback training for the generation module. According to the method, the defects in the prior art can be overcome, the feature extraction capability on the liver tumor data set is improved, and the training stability and the model generalization capability are enhanced.

The invention belongs to the technical field of biology, and particularly relates to a composition for tumor targeted therapy, hydrogel and a preparation method and application thereof. The tumor targeted therapy composition provided by the invention comprises the aging tumor cells and the celecoxib, the immune activation function of the aging tumor cells is that STCs can effectively activate the maturation of dendritic cells and the immune function of T cells and NK cells, SASP of the STCs is regulated through the celecoxib, especially generation of prostaglandin E2 is inhibited, and the tumor targeted therapy effect is improved. And the combined use further enhances the anti-tumor immune effect.

Disclosed in the present invention are an ecteinascidin compound and the use thereof. Provided in the present invention is a compound as represented by formula (I), or a pharmaceutically acceptable salt, an ester, a stereoisomer, a tautomer, a polymorph, a solvate, an isotopically labeled compound, a metabolite or a prodrug thereof. The compounds provided by the present invention have one or more effects selected from the following group: (1) having an inhibitory activity against tumor cell proliferation in vitro; (2) having a tumor inhibition effect in vivo; (3) having an in vivo tumor targeting capability; and (4) having good safety in vivo.

The invention discloses an AuAgPt ternary alloy nano-framework, a preparation method thereof and application of the AuAgPt ternary alloy nano-framework in anti-tumor preparations, and belongs to the field of biomedical nano-materials. The AuAgPt ternary alloy nano frame is a hollow octahedral nano frame formed by 12 AuAgPt ternary alloy edges, and the nano frame has plasmon photothermal conversion performance, catalase activity and peroxidase-like activity, and can be used for preparing the nano frame. The aptamer has the characteristics that the aptamer can form a covalent bond with glutathione (GSH), the aptamer with the framework surface capable of being modified and specifically bound with tumor cells is used for tumor targeted delivery and the like, the aptamer can be bound in a targeted manner and internalized into the tumor cells, and after near-infrared laser irradiation, the cell temperature can be increased to 42 DEG C, reactive oxygen species (ROS) can be generated, GSH can be consumed, and the tumor targeting effect is achieved. In addition, the content change of small molecule metabolites in cells can be driven through a low-temperature photothermal effect, the metabolic state is disturbed, the redox balance in the cells is destroyed, the tumor cells are induced to generate ferroptosis and apoptosis, and the low-temperature photothermal treatment of tumors is realized.

The present invention relates to combination therapies employing tumor targeted anti-CEA / CD3 bispecific antibodies and / or agents blocking PD-L1 / PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules that also target FAP, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

The invention discloses a tumor targeting reagent and application thereof in tumor diagnosis. The targeting reagent has strong affinity to tumors, strong specificity and no biotoxicity, is relatively stable in vivo, and can be used as a molecular probe to be applied to molecular imaging and / or treatment of various integrin alpha6 high-expression tumors; the targeting reagent provided by the invention comprises the tumor targeting peptide RWYDeA, and further comprises a radionuclide chelating agent, other connecting structures and a hydroxyl substitution structure, and the structure is beneficial to improving the tumor targeting property of the targeting reagent, prolonging the tumor binding time and achieving a better tumor diagnosis effect; the method can be used for preparing products for diagnosing / treating diseases related to high expression of integrin alpha6.

The invention relates to an immune sensitization IRE treatment platform based on NK cell membrane coated manganese carbonate. A manganese carbonate composite nano material is formed by coating the surfaces of manganese carbonate nano particles with cell membranes. According to the invention, higher tumor specificity enrichment is realized, non-target tissue accumulation and systemic toxicity risks are reduced, collaborative integration of tumor targeted delivery, immune activation and IRE ablation is realized, and compared with single IRE, anti-tumor immune response is significantly enhanced.

The invention discloses iron oxide nanoparticles capable of responding to particle size change in a tumor microenvironment and a preparation method of the iron oxide nanoparticles, and belongs to the technical field of biomedical nano materials. The nano-particle comprises an iron oxide nano-crystal core with the particle size of 3-5nm and a tumor microenvironment response layer coating the surface of the iron oxide nano-crystal core. The response layer contains groups, such as disulfide bonds, enzyme digestion peptide fragments and the like, which can respond to acidic pH, high-concentration reduced glutathione or matrix metalloproteinase and other tumor characteristic stimuli to generate structural changes. In a tumor microenvironment, the hydration particle size of the nanoparticles can be directionally and controllably converted from 3-20 nm to 20-100 nm (or reversely). The preparation method mainly comprises two steps of preparing the core by a thermal decomposition method and modifying the surface response layer. The technical problems of insufficient tumor targeted enrichment capacity, limited imaging contrast and difficulty in balancing permeation and retention caused by fixed particle size of the existing iron oxide nanoparticles are solved, and the accuracy and efficiency of tumor diagnosis and treatment can be remarkably improved.

The present invention provides an antibody-drug conjugate, a preparation method thereof, and an application thereof. The structural formula of the antibody-drug conjugate is as follows. Among them, mAb is the anti-HER2 antibody trastuzumab; the conjugate is obtained by Michael addition of the thiol group obtained by reducing the inter-chain disulfide bond of mAb with the linker-irinotecan conjugate LD038; n ranges from 1 to 10. The binding activity and internalization activity of the antibody-drug conjugate to various tumor target cells are not affected; compared with the same type of antibody-drug conjugate, the antibody-drug conjugate PRO1102 synthesized by the preparation method of the antibody-drug conjugate of the present invention shows certain advantages in terms of in vitro cytotoxicity to tumor cells, anti-tumor activity in rats in vivo, and in vivo pharmacokinetics.

The invention belongs to the technical field of biomedical functional dyes and probes, and relates to a fluorescent probe, in particular to a cyclodextrin-based near-infrared fluorescent probe, which is a conjugate formed by coating a fluorescent molecule with cyclodextrin. According to the near-infrared fluorescent probe disclosed by the invention, cyclodextrin is nested on a carbon chain of a fluorescent molecule, so that the water solubility, histocompatibility and safety are improved, the fluorescence lifetime is prolonged, the light stability is improved, and rapid transmission and response of ureters, lymphatic vessels and lymph nodes in vivo are realized; the method can be used for NIR-I and NIR-II imaging; a near-infrared fluorescence probe with targeting property can be formed by marking various tumor targeting molecules, so that accurate targeting fluorescence imaging of different types of tumors such as urogenital tumors, head and neck cancers, breast cancers and cervical cancers and metastatic lymph nodes in NIR-I and NIR-II windows is realized, and the near-infrared fluorescence probe can be applied to fluorescence imaging navigation in clinical operations.

The invention relates to a tumor target volume segmentation method and device and a storage medium. The method comprises the following steps: acquiring a medical image containing a target tumor; segmenting the target tumor in a spatial dimension according to the medical image to obtain a plurality of first target volumes which are located in the target tumor and are not overlapped; grouping the plurality of first target volumes to obtain a plurality of target volume groups; wherein each target volume group comprises at least one first target volume, and the adjacent first target volumes in the plurality of first target volumes are located in different target volume groups. According to the tumor target volume segmentation method and device and the storage medium provided by the invention, continuous irradiation of adjacent areas can be avoided through differential irradiation of different target volume groups, so that accumulated damage to surrounding normal tissues is reduced.

Provided herein are trispecific and / or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and / or trivalent binding proteins and uses of such binding proteins.

Provided in the present invention are a magnetic resonance guided charged particle beam radiotherapy apparatus and an electromagnetic navigation parameter debugging method for target point coordinates, belonging to the technical field of radiotherapy apparatuses. The present invention comprises a charged particle beam electromagnetic navigation apparatus. The charged particle beam electromagnetic navigation apparatus comprises a multi-stage electromagnetic navigation coil, a charged particle beam sequentially passing through the multi-stage electromagnetic navigation coil to generate a parallel charged particle beam with a direction consistent with the direction of a magnetic resonance main magnetic field; and an MR imaging apparatus, comprising an MR main magnetic field coil upper group and an MR main magnetic field coil lower group, an imaging therapy area being formed therebetween. The electromagnetic navigation parameter debugging method of the present invention comprises constructing a target cost function, optimizing electromagnetic navigation parameters based on a gradient information-free optimization algorithm, and determining and outputting optimal navigation parameters. According to the present invention, the charged particle beam parallel to the MR main magnetic field can be generated, thereby greatly reducing the influence of Lorentz force on the charged particle beam, enabling to reduce the positioning difficulty of the charged particle beam on a tumor target area under MR guidance, and improving the therapeutic accuracy.

The invention provides application of a near-infrared fluorescent probe of a targeted folate receptor in preparation of a near-infrared first region and near-infrared second region diagnostic drug, and relates to the technical field of organic fluorescent molecules. The folate receptor-targeted near-infrared fluorescent probe has a structural formula as shown in a formula I which is described in the specification. The near-infrared fluorescent probe provided by the invention has good tumor targeting capability and water solubility, also has near-infrared two-region developing capability, and has huge development potential and application prospect in fluorescence-guided intraoperative navigation. # imgabs0 #

The invention relates to the technical field of novel biological nanomaterials, in particular to a lung-targeted exosome complex as well as a preparation method and application thereof. The lung targeting type exosome complex is prepared from an NK cell exosome, lipid nanoparticles and an entrapped anti-tumor nucleic acid drug, the NK cell exosome is obtained by extracting a natural killer cell NK-92MI of a human malignant non-Hodgkin lymphoma patient through a differential centrifugation method. The anti-tumor nucleic acid drug is a specific nucleic acid drug targeting a key canceration driving gene in non-small cell lung cancer. The lung targeting type exosome complex prepared by the invention is an excellent and stable drug delivery carrier, has a good lung tissue targeting function, enhances the tumor targeting effect of the exosome, also exerts the tumor cell killing function of the exosome, and has important significance for the treatment of non-small cell lung cancer.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide and a nuclide marker and application thereof. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The cyclic peptide can label a diagnostic nuclide for PET imaging, or a therapeutic nuclide for intra-tumor irradiation therapy, using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention relates to the technical field of image processing, in particular to a small intestine capsule endoscope target detection method which comprises the following steps: acquiring a small intestine capsule endoscope image; the method comprises the following steps: constructing an improved RT-DETR network, inserting an SCSA module between a backbone network and a neck network of the RT-DETR, and introducing a DFM module behind a three-branch Fusion module of the neck network; and the improved RT-DETR network adopts a Focaler-IoU loss function. According to the method, the problem that the accuracy of recognizing the tumor target by using the small intestine capsule endoscope image through RT-DETR needs to be further improved is solved.

The invention relates to the technical field of medical image processing and radiotherapy, in particular to an OVH-based breast cancer automatic radiotherapy plan design method and system. Constructing a historical database, and integrating the image data of the patient, the delineation structure of the target region and the organ at risk and the dose information; calculating an OVH index, and quantifying a spatial geometrical relationship between the breast cancer tumor target region and the key endangered organ; and extracting a target area external expansion distance Lx corresponding to the specific volume x of the organ in the OVH curve and a dose value Dx corresponding to the volume point in the dose-volume histogram. And constructing a function model between Lx and Dx through linear regression analysis. And for a new patient, the system calculates the Lx value of the organ of interest of the new patient, inputs the value into the linear model, and predicts the corresponding radiotherapy dose Dx. According to the method provided by the invention, intelligent aided design of the breast cancer radiotherapy plan can be realized, and a scientific and acceptable dose prediction basis is provided.

The invention discloses a brain tumor detection method based on improved YOLO11, which aims at special properties of medical images and clinical requirements of brain tumor detection, and comprises the following steps: firstly, standardizing and dividing brain tumor medical image data; the method comprises the following steps: designing a multi-stage mixed expansion convolution residual module (BTSA-MFE), and embedding the BTSA-MFE modules in a backbone network and a neck network; designing a lightweight medical feature fusion module M IAFA, and embedding an MIAFA module in a backbone network; a medical image specialized dynamic adaptive internal intersection-to-union ratio loss module MDIOU is designed, bounding box regression is adaptively optimized through a tissue density sensing type dynamic proportion adjustment mechanism, and the positioning precision of tumor targets with fuzzy edges and irregular shapes is improved; after training is completed, the brain tumor medical image to be detected is input into the model, the detection result is output, and the detection precision is improved.

The invention belongs to the technical field of radiopharmaceuticals, and particularly relates to a GPC3 targeted polypeptide probe and application thereof. According to the polypeptide probe targeting GPC3, non-natural functional groups are introduced to modify polypeptide ligands so as to enhance affinity, radiolabeling is carried out, and the polypeptide probe is used for PET molecular imaging diagnosis. The polypeptide probe shows good tumor targeting in vivo, the uptake of tumor tissues is remarkably different from that of normal liver tissues, the background of the normal liver tissues is clear, and a powerful tool and a theoretical basis are provided for noninvasive precise diagnosis of GPC3 positive liver cancer.